Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead, HIV
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP).
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.
Biden administration and Gilead settle long-running battle over patents for HIV PrEP pills
After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills.
Gilead, government settle HIV drug patent dispute
Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.
Barchart on MSN
1h
Earnings Preview: What to Expect From Gilead Sciences’ Report
Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...
1d
Gilead Sciences Inc. stock rises Wednesday, still underperforms market
Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...
FiercePharma
23h
Gilead's Kite taps longtime Amgen alum as new global commercial head
Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...
5d
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
1d
Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges
Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
Zacks.com on MSN
1d
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Gilead Sciences (GILD) closed at $92.38, marking a +1.52% move from the previous day.
Morningstar
2d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
6h
The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
1d
Analysts Offer Insights on Healthcare Companies: Lyell Immunopharma (LYEL) and Gilead Sciences (GILD)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
HIV
Federal government of the United States
LEO
NASDAQ
Feedback